Inflammatory Bowel Disease Treatment Market By Drug Class (Amino salicylates, Corticosteroids, Immunomodulators, Biologics {Tumor Necrosis Factor (TNF) Inhibitors, Anti-Integrins, Interleukin Inhibitors}, JAK Inhibitors), By Disease Type (Ulcerative Colitis, Crohn's Disease), By Route of Administration (Injectable, Oral), By Distribution Channel (Hospital Pharmacy, Drug Store, Retail Pharmacy, Online Pharmacy), Global Market Size, Segmental analysis, Regional Overview, Company share analysis, Leading Company Profiles And Market Forecast, 2025 – 2035

Report Coverage:

By Drug Class

• Aminosalicylates
• Corticosteroids
• Immunomodulators
• Biologics
  • Tumor Necrosis Factor (TNF) Inhibitors
  • Anti-Integrins
  • Interleukin Inhibitors
• JAK Inhibitors

By Disease Type

• Ulcerative Colitis
• Crohn's Disease

By Route of Administration

• Injectable
• Oral

By Distribution Channel

• Hospital Pharmacy
• Drug Store
• Retail Pharmacy
• Online Pharmacy

By Region

North America

• U.S.
• Canada

Europe

• U.K.
• France
• Germany
• Italy
• Spain
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• Australia
• South Korea
• Singapore
• Rest of Asia Pacific

Latin America

• Brazil
• Argentina
• Mexico
• Rest of Latin America

Middle East & Africa

• GCC Countries
• South Africa
• Rest of Middle East & Africa

List of Companies:

• AbbVie Inc.
• Johnson & Johnson
• Takeda Pharmaceutical Company Limited
• Pfizer Inc.
• UCB S.A.
• Bristol-Myers Squibb Company
• Amgen Inc.
• Eli Lilly and Company
• Novartis International AG
• Biogen Inc.
• Gilead Sciences, Inc.
• Ferring Pharmaceuticals
• Celgene Corporation
• Allergan plc
• Roche Holding AG
• Sanofi S.A.
• Merck & Co., Inc.
• Teva Pharmaceutical Industries Ltd.